Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 80 Breast Neoplasms 52 Prostatic Neoplasms 42 Lung Neoplasms 29 Multiple Myeloma 28 Parkinson Disease 4, Autosomal Dominant Lewy Body 22 Neoplasms 21 Neoplasm Metastasis 20 Leukemia, Lymphocytic, Chronic, B-Cell 19 Colorectal Neoplasms 19 Carcinoma, Renal Cell 19 Ovarian Neoplasms 17 Squamous Cell Carcinoma of Head and Neck 13 Recurrence 12 Leukemia, Myeloid, Acute 12 Urinary Bladder Neoplasms 11 Small Cell Lung Carcinoma 11 Pancreatic Neoplasms 11 Myasthenia Gravis 11 Endometrial Neoplasms 11 Triple Negative Breast Neoplasms 10 Stomach Neoplasms 9 Non-Muscle Invasive Bladder Neoplasms 9 Nasopharyngeal Carcinoma 9 Lymphoma, Large B-Cell, Diffuse 9 Fallopian Tube Neoplasms 9 Lymphoma, Non-Hodgkin 8 Lymphoma, Follicular 8 Carcinoma 8 Burkitt Lymphoma 8

Interventions

fludrocortisone acetate 1 enzalutamide 1 Prednisone 1 Hydrocortisone 1 Dexamethasone 1 Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Prostate Cancer Metastatic × 30 days × Clear all

NCT06136624 2026-05-05

OMAHA-003

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡